CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
November 25th 2024
Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk muscle-invasive urothelial cancer after radical resection.
November 21st 2024
Risk for Heart Attack, Stroke Five-Fold in Older Patients One Month Before Cancer Diagnosis
January 18th 2019Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.
New Chemotherapy Combination Offers Improved Outcomes in Bladder Cancer
November 27th 2018Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.
Combination with Higher Dose of Yervoy Shows Promise in Bladder Cancer
November 6th 2018Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.
New Research Says Universal Lynch Syndrome Testing Should Be Expanded
October 22nd 2018While universal screening for Lynch syndrome is currently only recommended for patients with colorectal and endometrial cancers, a new study recently published in The American Journal of Surgical Pathology suggests this for patients with upper tract urothelial carcinoma, too.
Immunotherapy's Role in Advanced Bladder Cancer Continues to Evolve
October 5th 2018Immunotherapy has been a buzzworthy topic in the field of bladder cancer over the last couple of years. However, according to a Food and Drug Administration (FDA) safety warning, patients with metastatic disease may need to have their treatment altered.
New Test May Identify Those Unlikely to Respond to Popular Bladder Cancer Treatment
August 30th 2018While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.
A Deeper Look Into a 40-Year-Old Bladder Cancer Treatment: Bacillus Calmette-Guerin
August 23rd 2018CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.
Immunotherapy in Bladder Cancer: FDA Updates Labels, Approves Diagnostic Tools
August 17th 2018The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.
Two Large Trials Investigate Combination Immunotherapy in Bladder Cancer
July 31st 2018With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.
Pre-Surgical Bladder Cancer Treatment: What's Next
July 16th 2018Many questions still remain in the treatment of localized bladder cancer, like which patients are best suited to receive neoadjuvant (pre-surgery) chemotherapy – a procedure that could be beneficial to many, but comes with increased toxicity.
Gender May Play a Role in Immunotherapy Efficacy, Further Studies Are Warranted
June 29th 2018Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.